Corbus Pharma Q3 net loss widens to $23.3 mln

Corbus Pharmaceuticals Holdings

12/11/2025 13:12

Overview

Corbus Pharmaceuticals Q3 net loss widens to $23.3 mln, driven by clinical development costs

Company completed $75 mln public offering, extending cash runway into 2028

CRB-701 clinical data shows promising ORR in HNSCC, cervical, and bladder cancers

Outlook

Company plans to meet FDA in Q1 2026 for CRB-701 data review

Corbus expects to start CRB-701 Phase 2/3 study by mid-2026

Company to complete CRB-913 SAD/MAD study by end of 2025

Result Drivers

R&D - Operating expenses increased by $8.9 million to approximately $24.4 million for the three months ended September 30, 2025, compared to approximately $15.5 million for the three months ended September 30, 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$23.34 mln
Q3 Basic EPS
-$1.90
Q3 Operating Expenses
$24.42 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Corbus Pharmaceuticals Holdings Inc is $40.00, about 73.9% above its November 11 closing price of $10.42

Press Release: ID:nGNX7pWxqv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)